We are Quintrigen
We are on the road to correct mutated p53, whose dysfunction is responsible for 50% of all cancers. Our team of world-renowned scientists has been at the forefront of p53 research for more than four decades and we are backed by top international strategic partners.
Targeting p53: A guardian gone rogue
The normal wild type p53 is the most powerful tumor suppressor. It can prevent cancer by instructing the repair of damaged DNA, or alternatively triggering cell destruction when the DNA is irreparable. But p53 may stray from the path nature assigned it. The p53 gene itself can be damaged and become mutant, not only losing its tumor suppressor abilities but sometimes gaining oncogenic activities, opening the gate to cancer.
Our unique peptide-based approach
Quintrigen has identified a family of small peptides that can reeducate mutant p53 to resume its guardian job. With a touch of these peptides, we can refold mutant p53 into its natural conformation, stabilizing its structure and restoring its potent guardian activity.
It is as though we can turn the mutant p53 protein from foe to friend all at once.
Prof. Varda Rotter
